BIOGEN INC. (BIIB)

Biogen is a global biopharmaceutical company that discovers, develops and delivers therapies for people with serious and complex diseases. It has a broad portfolio of multiple sclerosis medicines, introduced the first approved treatment for spinal muscular atrophy (SMA), co-developed treatments addressing a defining pathology of Alzheimer's disease, and launched the first approved treatment targeting a genetic cause of ALS. It also markets the first and only drug approved in the U.S., the E.U. and certain other markets for Friedreich's ataxia (FA) in adults and adolescents aged 16 and older. Its pipeline is focused on neurology, specialized immunology and rare diseases, supported by internal research and development, external collaborations and acquisitions.

Marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for MS; SPINRAZA for SMA; SKYCLARYS for FA; and QALSODY for SOD1 ALS. Biogen collaborates with Eisai on LEQEMBI for Alzheimer's disease and with Supernus on ZURZUVAE for postpartum depression. Under arrangements with Genentech (Roche Group), it holds business and financial rights tied to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO and COLUMVI, plus options on other anti-CD20 therapies. It also commercializes biosimilars: BENEPALI (etanercept), IMRALDI (adalimumab) and FLIXABI (infliximab). Pipeline programs include felzartamab (Phase 3 studies in IgAN, PMN and AMR), litifilimab, salanersen for SMA (Phase 3 expected to begin in 2026), BIIB080 for Alzheimer's disease, and zorevunersen for Dravet syndrome, developed with Stoke Therapeutics.

The text describes markets mainly by geography and regulatory approvals. Products have been approved or are under review in the U.S., the E.U., the U.K., Japan, China, Canada, Australia and Brazil. The text does not describe customer types in detail. In 2025 Biogen acquired Alcyone Therapeutics, whose ThecaFlex DRx port and catheter device is intended to deliver SPINRAZA intrathecally. It also entered research or license arrangements with Dayra Therapeutics, Vanqua Bio and City Therapeutics, and a funding agreement with Royalty Pharma for the litifilimab program. It sold its U.S. rights to the TOFIDENCE biosimilar to Organon and its remaining European rights to BYOOVIZ and OPUVIZ.

Biogen's operations include end-to-end development, manufacturing and commercialization of acquired and licensed assets. Samsung Bioepis is a partner on the biosimilar ophthalmology products. The company is based in Cambridge, Massachusetts. In March 2025 it signed a lease for about 580,000 square feet at 75 Broadway, Cambridge, to become its global headquarters. The lease is expected to start May 31, 2028 for about 15.5 years and is part of a plan to cut its Massachusetts real estate footprint by about 40%.